C

Celltrion Pharm Inc
KOSDAQ:068760

Watchlist Manager
Celltrion Pharm Inc
KOSDAQ:068760
Watchlist
Price: 56 900 KRW -1.22% Market Closed
Market Cap: 2.4T KRW
Have any thoughts about
Celltrion Pharm Inc?
Write Note
Section:
 

Relative Value

The Relative Value of one Celltrion Pharm Inc stock under the Base Case scenario is 22 017.93 KRW. Compared to the current market price of 56 900 KRW, Celltrion Pharm Inc is Overvalued by 61%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
22 017.93 KRW
Overvaluation 61%
Relative Value
Price
C
Worst Case
Base Case
Best Case

Valuation Multiples

5.7
P/S
P/S
Price to Sales
5.7
vs History
88
vs Industry
15
Median 3Y
7.1
Median 5Y
8.5
Industry
2.4
More Details
150.1
P/E
P/E
Price to Earnings
150.1
vs History
46
vs Industry
1
Median 3Y
108
Median 5Y
144.4
Industry
20.8
More Details
44.3
P/OCF
P/OCF
Price to OCF
44.3
vs History
80
vs Industry
2
Median 3Y
91.5
Median 5Y
89.4
Industry
15.8
More Details
85.7
P/FCFE
P/FCFE
Price to FCFE
85.7
vs History
53
vs Industry
0
Median 3Y
-66.3
Median 5Y
87.5
Industry
22.9
More Details
6.3
P/B
P/B
Price to Book Value
6.3
vs History
87
vs Industry
7
Median 3Y
8.3
Median 5Y
9.1
Industry
2
More Details
5.9
EV/S
EV/S
Enterprise Value to Sales
5.9
vs History
90
vs Industry
13
Median 3Y
7.4
Median 5Y
8.7
Industry
2.5
More Details
22.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
22.7
vs History
76
vs Industry
6
Median 3Y
25.7
Median 5Y
28.6
Industry
5
More Details
52.2
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
52.2
vs History
63
vs Industry
4
Median 3Y
52.8
Median 5Y
59.6
Industry
13.1
More Details
88.7
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
88.7
vs History
57
vs Industry
2
Median 3Y
79.6
Median 5Y
90.4
Industry
16.2
More Details
46.5
EV/OCF
EV/OCF
Enterprise Value to OCF
46.5
vs History
84
vs Industry
2
Median 3Y
94.8
Median 5Y
93.6
Industry
14.7
More Details
51.6
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
51.6
vs History
60
vs Industry
1
Median 3Y
61.1
Median 5Y
61.1
Industry
18.4
More Details
4.6
EV/IC
EV/IC
Enterprise Value to IC
4.6
vs History
84
vs Industry
12
Median 3Y
5.9
Median 5Y
6.5
Industry
1.8
More Details

Multiples Across Competitors

Competitors Multiples
Celltrion Pharm Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
KR
Celltrion Pharm Inc
KOSDAQ:068760
2.5T KRW 5.7 150.1 52.2 88.7
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
753.9B USD 18.4 90 48.4 54
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.8T DKK 10.3 29.5 20.5 23.4
US
Johnson & Johnson
NYSE:JNJ
343.8B USD 3.9 23.4 11.3 14.8
US
Merck & Co Inc
NYSE:MRK
252.9B USD 4 20.8 10.5 12.6
CH
Roche Holding AG
SIX:ROG
214.1B CHF 3.6 18.6 10.5 12.4
UK
AstraZeneca PLC
LSE:AZN
170.1B GBP 4.3 32.5 169.8 254.5
CH
Novartis AG
SIX:NOVN
178.3B CHF 3.9 11.1 9.6 13.4
US
Pfizer Inc
NYSE:PFE
152.6B USD 2.5 35.9 10.6 16.1
P/E Multiple
Earnings Growth PEG
KR
C
Celltrion Pharm Inc
KOSDAQ:068760
Average P/E: 45.8
150.1
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
90
76%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
29.5
23%
1.3
US
Johnson & Johnson
NYSE:JNJ
23.4
-8%
N/A
US
Merck & Co Inc
NYSE:MRK
20.8
320%
0.1
CH
Roche Holding AG
SIX:ROG
18.6
16%
1.2
UK
AstraZeneca PLC
LSE:AZN
32.5
40%
0.8
CH
Novartis AG
SIX:NOVN
11.1
9%
1.2
US
Pfizer Inc
NYSE:PFE
35.9
102%
0.4
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
KR
C
Celltrion Pharm Inc
KOSDAQ:068760
Average EV/EBITDA: 419
52.2
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48.4
42%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
DK
Novo Nordisk A/S
CSE:NOVO B
20.5
22%
0.9
US
Johnson & Johnson
NYSE:JNJ
11.3
4%
2.8
US
Merck & Co Inc
NYSE:MRK
10.5
63%
0.2
CH
Roche Holding AG
SIX:ROG
10.5
7%
1.5
UK
AstraZeneca PLC
LSE:AZN
169.8
18%
9.4
CH
Novartis AG
SIX:NOVN
9.6
3%
3.2
US
Pfizer Inc
NYSE:PFE
10.6
9%
1.2
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
KR
C
Celltrion Pharm Inc
KOSDAQ:068760
Average EV/EBIT: 1 819.2
88.7
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54
45%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
DK
Novo Nordisk A/S
CSE:NOVO B
23.4
22%
1.1
US
Johnson & Johnson
NYSE:JNJ
14.8
9%
1.6
US
Merck & Co Inc
NYSE:MRK
12.6
98%
0.1
CH
Roche Holding AG
SIX:ROG
12.4
9%
1.4
UK
AstraZeneca PLC
LSE:AZN
254.5
32%
8
CH
Novartis AG
SIX:NOVN
13.4
17%
0.8
US
Pfizer Inc
NYSE:PFE
16.1
19%
0.8

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 216,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.